Skip to main content
Other
Preferential Killing of Cancer Cells and Activated Human T-Cells Using ZnO Nanoparticles
Boise State Patents
  • Alex Punnoose, Boise State University
  • Madhusudan R. Kongara
  • Denise Wingett, Boise State University
Document Type
Patent
Issued Date
5-29-2012
Assignee
Boise State University
Abstract
Here we disclose the response of normal human cells to ZnO nanoparticles under different signaling environments and compare it to the response of cancerous cells. ZnO nanoparticles exhibit a strong preferential ability to kill cancerous T cells (-28-35X) compared to normal cells. Interestingly, the activation state of the cell contributes toward nanoparticle toxicity as resting T cells display a relative resistance while cells stimulated through the T cell receptor and CD28 costimulatory pathway show greater toxicity in direct relation to the level of activation. The novel findings of cell selective toxicity towards potential disease causing cells indicate a potential utility of ZnO nanoparticle in the treatment of cancer and/or autoimmunity.
Comments

21 Claims, 9 Drawing Sheets

Citation Information
Alex Punnoose, Madhusudan R. Kongara and Denise Wingett. "Preferential Killing of Cancer Cells and Activated Human T-Cells Using ZnO Nanoparticles" (2012)
Available at: http://works.bepress.com/denise_wingett/19/